62nd ASH Annual Meeting and Exposition: 603. Oncogenes and Tumor Suppressors: Poster I

Oral and Poster Abstracts
Poster

Adult, ALL, AML, Biological, HSCs, Leukemia, multiple myeloma, Animal models, CLL, Diseases, Non-Biological, cell regulation, Therapies, chemotherapy, Genetic Disorders, MDS, Pediatric, B-Cell Lymphoma, Biological Processes, DNA damage, MPN, Technology and Procedures, Cell Lineage, cytogenetics, epigenetics, Plasma Cell Disorders, Xenograft models, gene editing, Lymphoid Malignancies, Study Population, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies, hematopoiesis, flow cytometry, TKI, molecular testing, NGS, RNA sequencing, pathogenesis, pathways, senescence, signal transduction

949

A Novel Human Fetal Model of CRISPR-Cas9-Induced MLL-AF4 Leukemia Faithfully Recapitulates Infant ALL and Can be Used to Unravel MLL-AF4 Function

Siobhan Rice¹^*, Nicholas T. Crump¹^*, Laura Godfrey¹^*, Thomas Jackson²^*, Nicholas James Fordham¹^*, Nicole Jackson¹^*, Sorcha Isabella O'Byrne²^*, Natalina Elliott²^*, Sarah Inglott³^*, Dariusz Ladon³^*, Gary Wright³^*, Jack Luke Bartram³^*, Philip Ancliffe³^*, Christina Halsey⁴, Irene Roberts, MD, PhD^1,2, Tom Arthur Milne¹ and Anindita Roy, MD, PhD²

¹MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Oxford Biomedical Research Centre Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
²Department of Paediatrics, University of Oxford, Oxford, United Kingdom
³Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom
⁴University of Glasgow, Glasgow, SCO, United Kingdom

950

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Yao Yao¹^*, Woojun D Park²^*, Eugenio Morelli, MD³, Mehmet Kemal Samur, PhD⁴^*, Nicholas P Kwiatkowski, PhD⁵^*, Yan Xu, MD⁶^*, Chandraditya Chakraborty, PhD⁷^*, Behnam Nabet, phD⁸^*, Marta Chesi, PhD⁹, Herve Avet-Loiseau^10,11, Nathaniel Gray¹²^*, Richard A. Young, PhD^13,14^*, Kenneth Anderson, MD^6,15,16,17, Charles Y Lin, PhD^18,19^*, Nikhil C. Munshi, MD^17,20,21,22 and Mariateresa Fulciniti, PhD⁶

¹Dana Farber Cancer Institute, Boston, MA
²Department of Molecular and Human Genetics, Baylor College of Medicine, Huston, TX
³Department of Medical Oncology, DANA FARBER CANCER INSTITUTE, Boston, MA
⁴Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁵Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁷Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁸Dana farber cancer institute, Boston, MA
⁹Department of Medicine, Mayo Clinic Arizona, Scottsdale, AZ
¹⁰Unite de Genomique du Myelome, IUC-T Oncopole, Toulouse, France
¹¹Universite Paul Sabatier, Toulouse, France
¹²Dana-Farber Cancer Institute, Boston, MA
¹³Department of Biology, Massachusetts Institute of Technology, Cambridge, MA
¹⁴Whitehead Institute for Biomedical Research, Cambridge, MA
¹⁵Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁶Dana-Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA
¹⁷Harvard Medical School, Boston, MA
¹⁸Dan L. Duncan Cancer Center, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX
¹⁹Dan L. Duncan Cancer Center, Department of Molecular and Human Genetics, Baylor College of Medicine, HOUSTON, TX
²⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²¹VA Boston Healthcare System, Boston, MA
²²The LeBow Institute for Myeloma Therapeutic and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

951

The Scaffolding Protein NEDD9 Regulates Chronic Lymphocytic Leukemia Cell Migration Via the CXCR4 - CXCL12 Axis and Promotes Disease Progression

Lisa Rusyn, PhD¹^*, Sebastian Reinartz¹^*, Anastasia Nikiforov¹^*, Nelly Mikhael¹^*, Christian Pallasch¹^*, Reinhard Buettner²^*, Michael Hallek¹, Phuong Hien Nguyen¹^* and Tamina Seeger-Nukpezah¹^*

¹University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Center for Molecular Medicine Cologne; CECAD Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany
²University of Cologne, Institute of Pathology, Cologne, Germany

952

Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms

Tristan L. Lim, BSc¹, David B. Lieberman, MS, CGC²^*, Adam R. Davis, MD³^*, Ryan Hausler, MS⁴^*, Ashkan Bigdeli, MS³^*, Yimei Li, PhD⁵^*, Jacquelyn Powers, MS, LCGC⁶^*, Regeneron Genetics Center⁷^*, Shannon A. Carty, MD⁸, Katherine L. Nathanson, MD⁹^*, Adam Bagg, MD³, Elizabeth O. Hexner, MD, MSTR⁶^*, Kara N. Maxwell, MD, PhD⁶^*, Jennifer J.D. Morrissette, PhD³^* and Daria V. Babushok, MD, PhD¹⁰

¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
²Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
³Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
⁴Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA
⁵Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
⁶Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
⁷Regeneron Pharmaceuticals Inc., Tarrytown, NY
⁸Division of Hematology-Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI
⁹Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
¹⁰Division of Hematology/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

953

Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an in Vitro model of a High-Risk Acute Lymphoblastic Leukemia

Charlotte EJ Downes, BS^1,2^*, Barbara J McClure, BSc, PhD^3,4^*, Jacqueline Rehn, MSc(BioTech)^3,4^*, James Breen, BSc, PhD^3,5,6^*, John B Bruning, BSc, PhD²^*, David T Yeung, BSc, PhD, FRACP, FRCPA, MBBS^3,7,8 and Deborah L White, PhD, FFSc(RCPA)^2,3,4,9

¹Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Sa, Australia
²School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia
³Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia
⁴Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia
⁵Computational and Systems Biology Program, Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia
⁶Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia
⁷Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia
⁸Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia
⁹Australian and New Zealand Childrens Haematology/Oncology Group (ANZCHOG), Melbourne, Australia

954

MDS1-EVI1 Complex (MECOM) Activation Promotes Leukemic Stem Cell Quiescence By Upregulating CDKN1C/P57^Kip2

Edward Ayoub, PhD, MS, BSc¹^*, Yi Zhang, PhD²^*, Michael Andreeff, MD, PhD¹ and Archibald S. Perkins, MD, PhD²

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY

955

Amot Inhibits Tumorigenesis of Diffuse Large B-Cell Lymphoma By Regulating DNA Damage Response

Tan Sang, PhD^1,2,3^*, Juan Yang, PhD^1,2^*, Jiarui Liu^2,4^*, Yang Han, MM^1,5^*, Ying Li, MD^1,2^*, Xiangxiang Zhou, MD^1,2^* and Xin Wang, MD, PhD^1,5

¹Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
²Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
³Department of Hematology, Jinan Central Hospital affiliated to Shandong University, Jinan, Shandong, China
⁴Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
⁵Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

603.P1.21 603. Oncogenes and Tumor Suppressors: Poster I